Apr. 20 at 2:01 PM
$LLY continues to aggressively expand its oncology footprint — multiple myeloma alone represents a ~
$40B+ global market opportunity, and the company is clearly signaling intent to compete at the highest level of treatment innovation.
The strategic angle here is platform expansion: if their in vivo / next-gen biologics approach continues to progress, it doesn’t just stay in late-line settings — it potentially moves into earlier treatment lines, which is where the real revenue scale sits.
This is no longer a single-market story. Lilly is positioning across multiple large therapeutic areas, with oncology first, and potential spillover into IBD next (
$SYRE watchlist relevance).
For context,
$JNJ and
$ABBV remain dominant incumbents in oncology and immunology respectively, but the competitive pressure is increasing as Lilly scales pipeline ambition across multiple
$100B+ markets (obesity, oncology, immunology).
